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Objectives. This study sought to assess the maximal rate of
acute Thrombolysis in Myocardial Infarction (TIMI) grade 3
patency that can be achieved in unselected patients.
Background. Early and complete (TIMI grade 3 flow) reperfu-
sion is an important therapeutic goal during acute myocardial
infarction. However, thrombolysis, although widely used, is often
contraindicated or ineffective. The selective use of primary and
rescue percutaneous transluminal coronary angioplasty (PTCA)
may increase the number of patients receiving reperfusion ther-
apy.
Methods. A cohort of 500 consecutive unselected patients with
acute myocardial infarction were prospectively treated using a
patency-oriented scheme: Thrombolysis-eligible patients received
thrombolysis (n 5 257) and underwent 90-min angiography to
detect persistent occlusion for treatment with rescue PTCA.
Emergency PTCA (n 5 193) was attempted in patients with
contraindications to thrombolysis, cardiogenic shock or uncertain
diagnosis and in a subset of patients admitted under “ideal
conditions.” A small group of patients (n 5 38) underwent acute
angiography without PTCA. Conventional medical therapy was
used in 12 patients with contraindications to both thrombolysis
and PTCA.
Results. Ninety-eight percent of patients received reperfusion
therapy (thrombolysis, PTCA or acute angiography), and angio-
graphically proven early TIMI grade 3 patency was achieved in
78%. Among patients with TIMI grade 3 patency, thrombolysis
alone was the strategy used in 37%, emergency PTCA in 40% and
rescue PTCA after failed thrombolysis in 15%; spontaneous
patency occurred in 8%.
Conclusions. Reperfusion therapy can be provided to nearly
every patient (98%) with acute myocardial infarction. Rescue and
direct PTCA provided effective early reperfusion to patients in
whom thrombolysis failed or was excluded.
(J Am Coll Cardiol 1997;30:157–64)
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Early and complete patency of the infarct-related artery is an
important therapeutic goal during the early hours of acute
myocardial infarction (1–7). Intravenous thrombolysis is the
most widely used reperfusion method. However, recent data
indicate that despite its proven benefit with regard to mortality
and morbidity (8–11), thrombolysis is still used in only a
minority of cases because of absolute or relative contraindica-
tion, because diagnosis is uncertain or patients do not fill the
electrocardiographic (ECG) criteria or because patients are in
cardiogenic shock (12–14). In addition, even contemporary
regimens of intravenous thrombolysis fail to achieve complete
Thrombolysis in Myocardial Infarction (i.e., [TIMI] flow grade
3) patency in 13% to 56% of patients (15). In the Global
Utilization of Streptokinase and t-PA for Occluded Coronary
Arteries (GUSTO) angiographic substudy, TIMI flow grade 3
patency was achieved in only 54% of patients treated with
accelerated tissue-type plasminogen activator (t-PA) (2). This
is an important limitation of thrombolysis, given recent data
indicating that only early and complete patency of the infarct-
related artery provides full clinical benefit (1,3,4). The use of
percutaneous transluminal coronary angioplasty (PTCA) for
patients excluded from thrombolysis (16,17) or with contrain-
dications (18) might substantially increase the proportion of
patients receiving reperfusion therapy. In addition, the use of
rescue PTCA as adjunctive treatment in patients with failed
thrombolysis would increase the proportion of patients achiev-
ing early TIMI flow grade 3 patency of the infarct-related
artery. Therefore, a majority of patients either never receive
reperfusion therapy or the therapy fails. The aim of the present
prospective study was to determine whether reperfusion ther-
apy could be applied to unselected patients with acute myo-
cardial infarction and to determine the maximal rate of acute
TIMI grade 3 patency that could be achieved using a patency-
oriented management approach (Fig. 1).
Methods
Study patients and enrollment criteria. From June 1988 to
January 1995, 500 consecutive, unselected patients with an
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acute myocardial infarction admitted to our institution ,6 h
after symptom onset were treated according to a previously
described patency-oriented scheme (19): patients with contra-
indications to thrombolysis (patients at high risk of bleeding),
an uncertain diagnosis, cardiogenic shock or ideal conditions
for primary PTCA (i.e., immediate availability of the catheter-
ization laboratory during daytime) underwent emergency cor-
onary angiography and, if the infarct-related artery was oc-
cluded (TIMI grade 0 or 1 flow), emergency angioplasty.
Patients without cardiogenic shock or contraindications to
thrombolysis received intravenous thrombolysis, using ac-
cepted protocols, and underwent 90-min emergency angiogra-
phy to ascertain the patency of the infarct-related artery. Age
alone was never a contraindication to thrombolysis. If flow in
the artery was TIMI grade 2 or 3, they were treated medically.
If flow was TIMI grade 0 or 1, they underwent rescue PTCA,
provided that the operator considered the infarct-related ar-
tery suitable for PTCA. A subset of patients underwent acute
coronary angiography because of a strong suspicion of spon-
taneous reperfusion and were treated medically when the
latter was confirmed. Conventional medical therapy was ap-
plied to patients with poor physiologic status and contraindi-
cations to both thrombolysis and vascular access.
The diagnosis of acute myocardial infarction was based on
conventional criteria: chest pain lasting .30 min and resistant
to nitrates, with typical ECG changes ($1-mV ST segment
elevation in two or more limb leads or $2-mV ST segment
elevation in two or more contiguous precordial leads on a
12-lead ECG). A small subset of patients had a typical chest
pain but atypical ECG changes: minor ST segment elevation,
giant T waves, left bundle branch block or accessory pathways.
The diagnosis of myocardial infarction was eventually con-
firmed in every case by creatine kinase elevation (more than
twice normal levels). Angiographic patency was defined as
TIMI grade $2 flow in the infarct-related vessel (20). Multives-
sel disease was defined as the presence of $50% lumen
diameter stenosis in at least two major epicardial arteries.
Medical treatment was as follows: All patients received
250 mg of intravenous aspirin acutely, followed by at least
250 mg daily until discharge. All patients undergoing emer-
gency angioplasty received 15,000 IU heparin intravenously at
the beginning of the procedure; the other patients received a
5,000-IU bolus. Subsequently, all patients received intravenous
heparin for at least 48 h (starting at 1,000 IU/h), adjusted to an
activated partial thromboplastin time two to three times con-
trol levels. Heparin was resumed immediately after catheter-
ization, except for those patients who had received a non–
fibrin-specific thrombolytic agent and in whom it was resumed
6 to 8 h later. All patients received beta-adrenergic blocking
agents, first intravenously then orally, unless contraindicated.
Before hospital discharge, patients underwent repeat coronary
angiography. Elective coronary artery bypass surgery during
the hospital stay was performed when severe triple-vessel
disease or left main coronary artery disease was present.
Statistical analysis. We first performed a bivariate analysis
using chi-square and Student t tests to determine the prognos-
tic factors of in-hospital mortality. Second, multivariate anal-
ysis was performed using linear logistic regression. Variables
used at this stage were those significantly linked to mortality in
the bivariate analysis (p , 0.05 was considered significant).
The final model was obtained using the best subsets method
(21), and the goodness of fit of the final model was assessed
using the Hosmer-Lemeshow method (22) (the samples are
ranked according to their calculated risk; they are divided in 10
equally sized classes; and, finally, the distribution of observed
and expected number of deaths are compared using the
chi-square test).
Results
Patient characteristics. Baseline characteristics are given
in Table 1 (mean [6SD] age 59 6 13 years; range 27 to 91;
25th, 75th percentiles 49, 68; 81.4% men). The average delay
between pain and admission to the coronary care unit was
184 6 89 min. Fifty-three percent of patients had single-vessel
disease on coronary angiography. Sixty percent of patients
were admitted at night or during weekends.
Intravenous thrombolysis. Intravenous thrombolysis was
used as reperfusion therapy in 257 patients (51% of the total
cohort). Standard regimens of the following agents were used:
recombinant tissue-type plasminogen activator (rt-PA) (n 5
140), streptokinase (n 5 75), rt-PA1urokinase (n 5 20),
anisoylated plasmin–streptokinase activated complex
(APSAC) (n 5 15) and rt-PA1streptokinase (n 5 7). Twenty
patients were included in the Urokinase and Alteplase in
Myocardial Infarction (URALMI) study (23), and 23 were
enrolled in the GUSTO angiographic substudy (2). One hun-
dred eighteen patients (46%) received prehospital thromboly-
sis in a mobile care unit. The overall time from symptom onset
to thrombolysis was 173 6 73 min; in patients receiving
prehospital thrombolysis this interval was 148 6 68 min, with
admission (drug to door time) on average 57 6 17 min later.
Time to thrombolysis was 193 6 75 min in patients receiving
in-hospital thrombolysis, with a door to drug time of 25 6
5 min. Ninety-minute angiography was performed in 244
(95%) of 257 patients receiving thrombolytic therapy. Angio-
graphically proven patency of the infarct-related artery was
TIMI grade 3 in 148 patients (57% of the 257 patients initially
Abbreviations and Acronyms
ECG 5 electrocardiographic
GUSTO 5 Global Utilization of Streptokinase and
t-PA for Occluded Coronary Arteries
NRMI 5 National Registry of Myocardial
Infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
rt-PA 5 recombinant tissue-type plasminogen
activator
TIMI 5 Thrombolysis in Myocardial Infarction
t-PA 5 tissue-type plasminogen activator
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treated with thrombolysis and 61% of the 244 undergoing
angiography), TIMI grade 2 in 21 and TIMI grade 0 or 1 in 75.
Among the 75 patients with a persistently occluded infarct-
related artery, rescue angioplasty was attempted in 59 and was
successful (TIMI grade 3 flow and ,50% residual stenosis) in
55 (93%). The time delay between admission and successful
rescue PTCA was 135 6 74 min, 31 6 35 min after angiography
and 291 6 102 min after symptom onset. Intracoronary stents
were required in three patients because of a large dissection.
Angiographically proven early TIMI grade 3 patency was thus
achieved in at least 203 patients (79% of those receiving
intravenous thrombolysis).
Emergency PTCA. Emergency angioplasty was performed
in 193 patients (39% of the cohort). The indication for
emergency angioplasty was a contraindication to thrombolysis
in 103 (Table 2), cardiogenic shock (combination of systolic
blood pressure ,80 mm Hg despite adequate volume expan-
sion and signs of acute cardiocirculatory failure) in 20 and
uncertain diagnosis in 26. In the 26 patients, diagnostic uncer-
tainty was related to the presence of giant T waves in 16
patients, minor ST elevation ,1 mV in 7, left bundle branch
block in 1 and accessory pathways in 2. Another 44 patients
without contraindications to thrombolysis were admitted under
“ideal conditions” for emergency PTCA. Adjunctive intraaor-
tic balloon pumping was used in 15 patients with cardiogenic
shock. An intracoronary stent was required in one patient
because of a large dissection. The success rate was similar
regardless of the indication for primary PTCA: 91% in patients
undergoing PTCA for contraindications, 90% in those with
cardiogenic shock, 88% in those with an uncertain diagnosis
and 93% in those treated with emergency PTCA under “ideal
conditions.” Overall, angiographically proven TIMI grade 2 or
3 patency was achieved in 176 patients (91% of the patients
who underwent direct PTCA) and was TIMI grade 3 flow in
158 (82%). The average time between admission and TIMI
grade 3 patency was 45 6 12 min.
Table 1. Patient Characteristics
Age (yr) 59 6 13
Men (%) 81.4
Time to admission (min) 184 6 89
Infarct location
Anterior 255 (51%)
Inferior 235 (47%)
Lateral 7 (1.4%)
Circumferential 3 (0.6%)
Previous myocardial infarction 60 (12%)
Contraindication to thrombolysis 133 (26.6%)
Cardiogenic shock on admission 31 (6.2%)
Risk factors
Smoking 72%
Dyslipidemia 42%
Hypertension 37%
Family history of CAD 29%
Diabetes mellitus 13%
Data presented are mean value 6 SD or percent or number (%) of patients.
CAD 5 coronary artery disease.
Figure 1. Management strategy for entire cohort. AMI 5 acute
myocardial infarction; angio 5 coronary angiogram; CI 5 contraindi-
cation; IRA 5 infarct-related artery; IV 5 intravenous; PTCA 5
percutaneous transluminal coronary angioplasty; Rx 5 treatment; T 5
thrombolysis; TIMI 5 Thrombolysis in Myocardial Infarction flow
grade.
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Acute angiography without PTCA. Angiography demon-
strated spontaneous reperfusion of the infarct-related artery in
31 patients (TIMI grade 3 flow in 30 and TIMI grade 2 flow in
1) or small size of the occluded infarct-related artery (deemed
unworthy of mechanical desobstruction) in 7.
Conventional medical therapy. Conventional medical
treatment without reperfusion therapy was applied to 12
elderly patients (81 6 9 years old) with very poor physiologic
status because of contraindications to both thrombolysis and
vascular access.
Reperfusion. Reperfusion therapy (intravenous thrombol-
ysis, primary PTCA or acute angiography) was attempted in
488 (98%) of 500 patients and provided angiographically
proven acute TIMI grade 3 patency in 391 (78%); overall, 431
(86%) of 500 patients achieved angiographically proven acute
TIMI grade 2 or 3 patency (Table 3, Fig. 2). In addition to the
148 patients in whom intravenous thrombolytic therapy re-
sulted in TIMI grade 3 patency, rescue PTCA after failed
thrombolysis provided patency in 55 and emergency PTCA in
an additional 158. Angiography demonstrated spontaneous
reperfusion (TIMI grade 3 flow) in 30 patients. Of the 129
patients who were not eligible for thrombolysis (103 for
contraindications and 26 for an uncertain diagnosis), early
TIMI grade 3 patency was achieved by emergency PTCA in
109. Among patients with TIMI grade 3 patency, thrombolysis
alone was the strategy used in 37%, whereas 55% achieved
TIMI grade 3 patency by either emergency PTCA (40%) or
rescue PTCA after failed thrombolysis (15%); 8% achieved
spontaneous TIMI grade 3 patency (Fig. 3).
Mortality. The in-hospital mortality rate was 9.4% (47
patients): 10 (3.9%) of 257 patients treated by intravenous
thrombolysis, including 2 (3.4%) of 59 treated with rescue
PTCA; 31 (16%) of 193 treated by direct PTCA; none of 37
with spontaneous reperfusion; 2 (28%) with a small infarct-
related artery unsuitable for PTCA; and 4 (33%) of 12 treated
Figure 2. TIMI flow grade in the infarct-related vessel immediately
after reperfusion therapy.
Table 2. Contraindications for Thrombolytic Therapy
No. of
Patients
Prolonged cardiac massage 17
Systolic blood pressure .200 mm Hg 8
Oral anticoagulant therapy 3
History of cerebrovascular accident 9
Known bleeding disorder 3
Inability to communicate (language) 5
Intramuscular injection 6
Recent arterial puncture 7
In previous 3 mo
Gastrointestinal bleeding 25
Operation 9
Major trauma 8
Urologic bleeding 2
Hemoptysis 1
Total 103
Table 3. Reperfusion
Treatment
No. of
Pts
TIMI Flow Grade
Mortality3 2 0–1 Unknown
IV6rescue PTCA 257 203 (79%) 21 17 16 10 (3.9%)
T alone 198 148 (57%) 21 13 16 8 (4.1%)
Rescue PTCA 59 55 (95%) — 4 — 2 (3.2%)
Emergency PTCA 193 158 (82%) 18 17 0 31 (16%)
CI to T 103 86 (84%) 8 9 — 8
Uncertain diagnosis 26 23 (85%) 1 2 — 0
“Ideal conditions” 44 37 (86%) 3 4 — 6
Cardiogenic shock 20 12 (55%) 6 2 — 17
Acute angiography without PTCA
Small IRA 7 — — 7 — 2 (28%)
Spontaneous reperfusion 31 30 1 0 — 0
Conventional medical therapy 12 — — — 12 4 (33%)
Total 500 391 (79%) 40 41 28 47 (9.4%)
Data presented are number or number (%) of patients (Pts). CI 5 contraindication; IRA 5 infarct-related artery;
IV 5 intravenous; PTCA 5 percutaneous transluminal coronary angioplasty; T 5 thrombolysis; TIMI 5 Thrombolysis
in Myocardial Infarction.
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by conventional medical therapy. The mortality rate was 6.6%
(26 of 391) among patients with angiographically proven TIMI
grade 3 flow, 17.5% (7 of 40) for TIMI grade 2 patency and
18.8% (13 of 69) for TIMI grade 0 or 1 patency or unknown
status of the infarct-related artery. When patients in cardio-
genic shock were excluded, the mortality rate was 6% overall
and 7.25% in the emergency PTCA group.
Prognostic factors of in-hospital mortality. Using bivariate
analysis, the following factors were significantly correlated with
in-hospital mortality: age (p , 0.0001), female gender (p ,
0.004), hypertension (p , 0.02), lack of family history of
coronary artery disease (p , 0.04), lack of smoking history
(p , 0.001), previous myocardial infarction (p , 0.04), mul-
tivessel disease (p , 0.001), anterior location (p , 0.02),
cardiogenic shock (p , 0.001) and failed acute TIMI grade 3
patency (p , 0.001). These variables were included in the
multivariate analysis, performed using linear logistic regres-
sion. Model selection was performed with the best subsets
method, the results of which are displayed in Table 4. The best
model with one variable is obtained with cardiogenic shock,
and the best model with two variables includes cardiogenic
shock and age. Because these models are embedded, they can
be compared using the log-likelihood ratio test, and the
two-variable model is significantly better. When three variables
are included, there is no significant improvement over the
two-variable model. The variables used in this model are
displayed in Table 4. The fit obtained by this model is very
good, as shown by the method of Hosmer and Lemeshow (22):
This method gives a statistic test value of 1.9597, correspond-
ing to a chi-square variable of 8 degrees of freedom (p , 0.98)
(Fig. 4).
Bleeding complications. Major hemorrhagic complications
occurred in 37 patients (7.4%), requiring blood transfusions in
27 (5%). Four fatal cerebral hemorrhages occurred after
thrombolysis, despite no patient having obvious contraindica-
tion to thrombolysis before initiation of therapy. Of the 33
remaining patients, 2 had a retroperitoneal hematoma, 17 had
Figure 3. Treatment strategy used to achieve early TIMI grade 3
patency.
Figure 4. Relation between observed and expected mortality in the 10
classes of equal size as defined by the Hosmer-Lemeshow method. The
close relation between the two curves illustrates that the fit obtained
with this model is very good.
Table 4. Results of Best Subsets Method and Logistic Regression
No. of
Variables
Score Value
(2 log-likelihood) Variables Included in Model
1 179.5427 Shock
1 50.9481 Age
1 29.6269 No smoking history
2 206.4119 Age1shock
2 187.6322 No smoking history1shock
2 186.8533 Shock1TIMI flow grade ,3
3 209.0339 Age1shock1TIMI flow grade ,3
3 207.5938 Age1multivessel disease1shock
3 207.3818 Age1no smoking history1shock
Variable Parameters SE p Value
Odds
Ratio
Intercept 10.3141 1.3982 0.0001
Age 20.1104 0.0189 0.0001 0.895
Shock 24.5564 0.5946 0.0001 0.010
TIMI 5 Thrombolysis in Myocardial Infarction.
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peri–access site bleeding (requiring surgical repair in 3), and 4
had gastrointestinal hemorrhage. Finally, 10 patients had a fall
in hemoglobin .5 mg/dl, requiring transfusion, but without
overt bleeding.
Reocclusion. Repeat angiography was performed in 378 of
500 patients just before discharge. Of the 391 patients with
proven early TIMI grade 3 patency, reocclusion was detected
in 27 (7%) (symptomatic in 11 and silent in 16), and TIMI flow
fell to grade 2 in one patient; therefore 298 patients had
persistent TIMI grade 3 flow (65 patients had no angiography
at discharge) (Fig. 5). In 40 patients with TIMI grade 2 flow,
repeat angiography showed an improvement to TIMI grade 3
patency in 18, no change in 2 and occlusion (TIMI grade 0 or
1 flow) in 5 (15 had no repeat angiography). Finally, in 41
patients with TIMI grade 0 or 1 flow in the infarct-related
artery initially, TIMI grade 3 patency was seen in 9, TIMI
grade 2 patency in 2 and persistent occlusion in 8 (22 had no
repeat angiography). Of the 28 patients with no angiography
during the acute phase, 10 underwent predischarge angiogra-
phy, which demonstrated TIMI grade 3 flow in all 10. There-
fore, 335 (67%) of 500 patients had angiographically proven
TIMI grade 3 patency at discharge.
Discussion
Data from several countries indicate that only a minority of
patients with acute myocardial infarction are eligible for
thrombolysis (13,14,16,17,24,25). Recently, classical restric-
tions to the use of thrombolytic therapy have been challenged
(26–30) in an attempt to strictly limit contraindications, widen
the time interval for inclusion (31,32) and to ensure that no
eligible patient is unduly excluded. However, recent data from
the large National Registry of Myocardial Infarction (NRMI)
(12) still indicate that only a minority of patients (31%) receive
thrombolysis. In addition, even marginal widening of the
indications for thrombolysis may markedly increase the risk of
hemorrhagic stroke (33).
Reperfusion. The main finding of this study is that by using
a therapeutic strategy that does not rely solely on intravenous
thrombolysis to achieve reperfusion, the proportion of patients
with an acute myocardial infarction undergoing reperfusion
therapy can be substantially increased. Indeed, nearly all the
patients from the present cohort underwent reperfusion ther-
apy. A subset of patients in whom early angiography demon-
strated “spontaneous” early TIMI grade 3 patency of the
infarct-related artery did not require emergency PTCA but
were treated medically, without incurring the hemorrhagic
risks of unnecessary thrombolysis. In addition, the adjunctive
use of rescue angioplasty in case of failed thrombolysis allowed
the achievement of an angiographically proven early TIMI
grade 3 patency rate of 78% (which was probably underesti-
mated because 25 patients did not undergo emergency angiog-
raphy).
Mortality. The overall mortality rate was 9.4%. Although
this rate may appear somewhat high, the patients were consec-
utive and unselected, particularly with respect to contraindica-
tions to thrombolysis or age (13). Whereas the effectiveness of
intravenous thrombolysis is considered to be poor in patients
with cardiogenic shock (8,9), improved survival has been
reported after primary PTCA (34,35). The high mortality rate
(71%) observed in patients with cardiogenic shock, despite the
high reperfusion rate and the liberal use of intraaortic balloon
pumping, together with data from other studies (36,37), sug-
gest that this approach may not be sufficient for patients with
early cardiogenic shock. The apparent high mortality rate
among patients treated by emergency angioplasty can be
ascribed, at least in part, to the patients admitted with cardio-
genic shock, as well as to a tendency to bias elderly patients
toward primary PTCA (patients receiving thrombolysis were
on average 5 years younger than those treated with primary
PTCA for contraindications to thrombolysis or under ideal
conditions).
Noninvasive detection of reperfusion. Simple clinical and
ECG data are poor indicators of infarct-related vessel patency
(38). New noninvasive methods remain to be validated pro-
spectively (39,40) or achieve suboptimal results (40–42). Rou-
tine emergency angiography had several advantages: It pro-
vided early information on coronary anatomy and allowed the
identification of patients with spontaneous reperfusion. Fur-
thermore, angiography alone has been reported to improve the
patency rate by 5% to 8% (15,43).
Figure 5. In-hospital outcome of patients with angio-
graphically proven acute TIMI grade 3 patency of the
infarct-related artery. CABG 5 coronary artery bypass
graft surgery; other abbreviations as in Figure 1.
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Rescue angioplasty. The benefit of rescue angioplasty is
controversial (44,45). The Randomized Evaluation of Sal-
vage Angioplasty With Combined Utilization of Endpoints
(RESCUE) trial (46) demonstrated benefit after failed throm-
bolysis for anterior acute myocardial infarction. Whether this is
applicable to patients with inferior infarction or with TIMI
grade 2 flow in the infarct-related vessel remains to be
determined, although there is abundant evidence that achiev-
ing TIMI grade 2 flow is not associated with the same clinical
benefit as TIMI grade 3 flow (2,4,47,48).
Study limitations. This was a single-center cohort, and
there may have been a recruitment bias in favor of patients
with mild myocardial infarction or young age. However, 19%
of the patients were .70 years old, a proportion similar to that
in the NRMI registry (12). The rate of stenting during primary
or rescue PTCA was low. The results of emergency PTCA may
be improved by the routine use of stenting (49).
Conclusions. By adding emergency and rescue PTCA to
intravenous thrombolysis in the therapeutic armamentarium
used during acute myocardial infarction, it is possible to
provide reperfusion therapy to nearly all patients with myocar-
dial infarction. In unselected patients, this strategy achieved a
high rate of angiographically proven early TIMI grade 3
patency (78%). The number of patients with early patency was
more than twice that provided by intravenous thrombolysis
alone.
We are indebted to the catheterization team (Joelle Cabanes, Jacqueline
Latulipe, Cecile Potier, Francois Dubroca) and to the nurses of the Coronary
Care Unit of Hoˆpital Bichat for their participation in round the clock catheter-
ization effort.
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